| LDL and cardiovascular disease: Latest insights |
| | New Approaches to LDL Reduction and HDL Increase |
|
| Ezetimibe strongly increases TICE |
| | Prospective Clinical Events Trials Examining the Effects of Statins in ESRD Patients |
|
| Relationship Between GFR and CVD Outcomes |
| | 4D Study |
|
| 4D Study |
| | AURORA Study |
|
| AURORA Study Design |
| | AURORA Study: Cumulative Incidence of Primary Endpoint |
|
| The results of the Study of Heart and Renal Protection (SHARP) |
| | SHARP: Rationale |
|
| SHARP: Eligibility |
| | SHARP: Assessment of LDL-lowering |
|
| SHARP: Baseline characteristics |
| | SHARP: Compliance and LDL-C reduction at study midpoint |
|
| SHARP: Baseline paper and Data Analysis Plan |
| | SHARP: Main outcomes |
|
| SHARP: Major Atherosclerotic Events |
| | CTT: Effects on Major Atherosclerotic Events |
|
| CTT: Effects on Major Atherosclerotic Events |
| | SHARP: Major Vascular Events |
|
| SHARP: Effects in subgroups |
| | SHARP: Major Atherosclerotic Events by renal status at randomization |
|
| SHARP: Cause-specific mortality |
| | SHARP: Renal outcomes |
|
| SHARP: Cancer incidence |
| | SHARP: Safety |
|
| SHARP: Conclusions |
| | The Inhibition of Cholesterol Ester Transfer Protein |
|
| CETP Levels and CAD risk: The EPIC – Norfolk study |
| | Scientific Case for Developing the CETP inhibitor Anacetrapib |
|
| Anacetrapib Dose Ranging Study |
| | Effect of HDL from Anacetrapib-treated Patients on Cholesterol Efflux from Human Macrophages |
|
| Effect of Torcetrapib and Anacetrapib on Blood Pressure in Rhesus Monkeys |
| | The Effect of Torcetrapib and Anacetrapib on Aldosterone Secretion from Primary Rat Adrenocortical Cells |
|
| Effects on LDL-C and HDL-C |
| | Conclusion |
|
| Future |
| | Nicotinic Acid Treatment of Dyslipidemia and Atherosclerosis |
|
| Niacin Raises HDL-C and Decreases LDL-C, TG, and Lp(a) in a Dose-Dependent Manner |
| | Effectiveness of 2 g vs 1 g of ER Niacin |
|
| Most Patients on ER Niacin Therapy Do Not Reach a 2-g Dose |
| | Niacin Flushing Pathway: Two Separate Steps and Sites of Action |
|
| Lipid/Flushing Study: Lower Incidence of Moderate or Greater Flushing vs ER Niacin |
| | Factorial Study: Lipid Efficacy |
|
| HPS2-THRIVE |
| | Conclusion |
|
Deel deze pagina met collega's en vrienden: